Close
Blog & Resources Camargo Blog March 19th, 2009

One vs. Two Batches for Single-Dose and Multiple-Dose Studies

Today’s posting stems from a client question. The client’s product candidate is an oral product that requires both single- and multiple dose pharmacokinetic studies.

Question: Do companies ever use one pivotal batch for single-dose (SD) study and another batch for the multi-dose (MD) study? What are the pros and cons of doing this?

See the table below for detailed pros and cons considering one batch for both SD and MD studies or one batch for SD study and one batch for MD study. The two primary drivers of the decision process will be the risk of failure due to the increased number of runs and secondarily the cost incurred which will vary depending on the materials and process involved. Also included in the decision process should be the examination of the strength of the pharmaceutical development program and documentation. Below the table, four cases are presented and recommendations made on how to proceed.

**Considerations****One batch for both SD and MD studies** **One batch for SD and another for MD**
**Pros** **Cons** **Pros** **Cons**
**Cost**Minimum upfrontMay have to spend more later to understand critical processing issuePotential to get experience with different batches of APIMore cost upfront, mfg, API, testing and documentation
**API and excipients**One batch of API and excipients in humans, all data consistentLess experience with suppliersUse of multiple lots of API and excipientsRisk of batch failure is higher
Potential to qualify a range of impurities
Additional experience with supplier
Additional testing and review
**Stability**One lot to support applicationNo back-up for failure on long-term stabilityMultiple stability lotsMore testing and drug handling
Back-up if failure occurs to support root-cause investigation
More robust support for application overall
More experience handling drug product
**Manufacturing**>One manufacturing run prior to approval (in 1:10 ratio compared to the commercial scale)Risk of problems due to inexperienceMore hands-on experience prior to approvalOpportunities for failures increased
Supports the expertise in the development of this product
Allows insight into batch variability (a little or a lot)
**FDA View**AcceptableIf there is not enough pharmaceutical development documentation, they may ask for more supportive information.AcceptableNone
Provides more information from a pharmaceutical development perspective. FDA is looking for depth here.

Selected cases with recommendations:

Case 1: A research and development program which demonstrates depth of experience at various scales with no apparent issues with the API or excipients. In this case one batch for both studies would be sufficient (there would be no problem submitting two).

Case 2: A research and development program which demonstrates poor reproducibility during the production of small scale batches, with little or no experience at one tenth commercial scale would be a case where multiple batches would be recommended to demonstrate control, safety and quality adequate for commercial scale.

Case 3: A research and development program for a new variation on an already marketed drug product, where there is full documentation at various scales and stability is well demonstrated. Upon evaluation of the pharmaceutical development documentation no issues were found, this program could be supported with only one batch (again there would be no problem with two different batches).

Case 4: An abbreviated research and development program for a new variation on an already marketed product, where there are few controls in place and multiple variations in historical lots. In order to build a case for a well controlled, quality process multiple batches would be recommended.

Lynn Gold, Camargo VP of CMC provided this post.


Categories: Clinical / CMC / Services

Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.


Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.


Contact
Headquarters
9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
2505 Meridian Parkway
Suite 150
Durham NC, 27713
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights